Chemical Information | |
Antiviral agent ID | DrugRepV_4598 | |
Antiviral agent name | 7-[(3-chlorophenyl)methoxy]-8-hydroxy-3-[(3-iodophenyl)methoxy]-1,4-dihydronaphthalen-1-one | |
IUPAC Name | 7-[(3-chlorophenyl)methoxy]-8-hydroxy-3-[(3-iodophenyl)methoxy]-1,4-dihydronaphthalen-1-one | |
SMILES (canonical) | OC1=C(OCC2=CC(Cl)=CC=C2)C=CC2=C1C(=O)C=C(C2)OCC1=CC(I)=CC=C1 | |
Molecular Formula | C24H18ClIO4 | |
Molecular Weight (g/mol) | 532.76 | |
InChl | InChI=1S/C24H18ClIO4/c25-18-5-1-3-15(9-18)14-30-22-8-7-17-11-20(12-21(27)23(17)24(22)28)29-13-16-4-2-6-19(26)10-16/h1-10,12,28H,11,13-14H2 | |
Structural Information | |
|
|
Clinical Information | |
Biological Information | |
Secondary Indication | Severe acute respiratory syndrome coronavirus (SARS-CoV) NA NA | |
Secondary Indication (Approaches) | Experimental | |
Secondary Indication (Methods) | In-vitro | |
Secondary Indication (Model system) [cell lines/ animal models] | Huh-7
| |
Secondary Indication (Mode of drug delivery) | Culture
| |
Secondary Indication (Time of drug delivery) | Post infection
| |
Secondary Indication (Duration of drug delivery) | 24 hours
| |
Secondary Indication (Drug concentration) | 23 μM
| |
Secondary Indication (Cell based assay) | Luciferase assay
| |
Secondary Indication (Change) | Decrease
| |
Secondary Indication (Type of Inhibition) | IC50 [ 50 % ] | |
Secondary Indication (Cytotoxicity) | >50 μM | |
Reference | Kim MK, Yu MS, Park HR, Kim KB, Lee C, Cho SY, Kang J, Yoon H, Kim DE, Choo H, Jeong YJ, Chong Y..2,6-Bis-arylmethyloxy-5-hydroxychromones with antiviral activity against both hepatitis C virus (HCV) and SARS-associated coronavirus (SCV)..Eur J Med Chem. 2011 Nov;46(11):5698-704. doi: 10.1016/j.ejmech.2011.09.005. Epub 2011 Sep 8. PMID:21925774
| |
Comment | NA
| |